Date: 2012-04-19
Type of information: Collaboration agreement
Compound: “bench-to-bedside” ophthalmology research services
Company: Iris Pharma (France) RxGen (USA)
Therapeutic area: Ophtalmological diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: Iris Pharma, a leading ophthalmic preclinical and clinical contract research organization (CRO), and RxGen, a specialty preclinical CRO focused on the development and application of translational research models, have established a strategic alliance to offer fully integrated “bench-to-bedside” ophthalmology research services to the global pharmaceutical and biotechnology industries. Under the newly forged transatlantic alliance, Iris Pharma can offer immediate access to RxGen’s non human primate ophthalmic research models and related preclinical in vivo services, via a flexible engagement model, that allows customers to benefit from the combined preclinical and clinical insight, capabilities, and expertise that RxGen and Iris Pharma collectively represent.
Iris Pharma services include proof of concept and GLP-compliant preclinical studies (safety, tolerance, pharmacokinetics, efficacy), bioanalysis, preclinical formulation, clinical trials and consulting services. Iris Pharma’s research facilities are GLP compliant.
RxGen, Inc. is a specialty preclinical CRO, providing innovative in vivo disease modeling and related preclinical research and development services to meet translational research needs of the global pharmaceutical and biotechnology industries. RxGen accelerates therapeutic and medical technology evaluation by the application of in vivo disease modeling and pharmacokinetic, pharmacodynamics and safety assessments, with deep therapeutic domain expertise in ophthalmology, central nervous system, metabolic and cardiac diseases and disorders. RxGen’s research facilities are AAALAC accredited and GLP compliant, supporting a range of services, from proof-of-concept through IND-enabling / regulatory studies.
Financial terms:
Latest news:
